The impact of inflammatory bowel diseases on the development of atherosclerosis and cardiovascular risk

Objective: To study the impact of inflammatory bowel diseases (IBD) on the development of atherosclerosis and assess cardiovascular risk in patients without established cardiovascular pathology. Materials and Methods. The study included 115 patients divided into three groups: 37 patients with Crohn’s disease (CD), 44 patients with ulcerative colitis (UC), and 34 patients in a control group without signs of IBD or other risk factors. All participants underwent carotid artery ultrasound (CAU), assessment of 10-year cardiovascular risk using the Framingham scale, and evaluation of basic laboratory parameters. Results. Patients with IBD demonstrated an increased intima-media thickness (IMT) of the common carotid artery (CCA): in the UC group, the IMT on the right side was 0.08 cm, and on the left side was 0.07 cm (p=0.019 and p=0.012, respectively); in the CD group, the IMT was 0.07 cm (p=0.001). In the control group, the IMT was 0.06 cm. Levels of C-reactive protein (CRP) and fibrinogen were significantly higher in the IBD groups compared to controls. The calculation of 10-year cardiovascular risk using the Framingham scale revealed no significant differences between the groups: the median risk was 1.54% [0.99-2.68] for the CD group, 1.59% [1.25-2.7] for the UC group, and 1.32% [1.04-2.17] for the control group (p=0.625). The number of patients with moderate and high risk (>10%) also did not differ significantly between the groups (p=0.135). Conclusion: IBD is associated with thickening of vascular walls and elevated levels of inflammatory markers, which may indicate an increased risk of developing atherosclerosis. However, the cardiovascular risk calculated using the Framingham scale did not differ significantly between the groups, highlighting the potential need for additional risk assessment in patients with IBD.

1. Townsend N, Kazakiewicz D, Lucy Wright F, et al. Epidemiology of cardiovascular disease in Europe. Nat Rev Cardiol. 2022;19(2):133-143. https://doi.org/10.1038/s41569-021-00607-3

2. Wolf D, Ley K. Immunity and Inflammation in Atherosclerosis. Circ Res. 2019;124(2):315-327. https://doi.org/10.1161/CIRCRESAHA.118.313591

3. Libby P. Inflammation in Atherosclerosis—No Longer a Theory. Clin Chem. 2021;67(1):131-142. https://doi.org/10.1093/clinchem/hvaa275

4. Su W, Zhao Y, Wei Y, Zhang X, Ji J, Yang S. Exploring the Pathogenesis of Psoriasis Complicated With Atherosclerosis via Microarray Data Analysis. Front Immunol. 2021;12. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.667690

5. Arida A, Protogerou AD, Kitas GD, Sfikakis PP. Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases. Int J Mol Sci. 2018;19(7). https://doi.org/10.3390/ijms19071890

6. Adawi M, Firas S, Blum A. Rheumatoid Arthritis and Atherosclerosis. Isr Med Assoc J IMAJ. 2019;21(7):460-463.

7. Cainzos-Achirica M, Glassner K, Zawahir HS, et al. Inflammatory Bowel Disease and Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. 2020;76(24):2895-2905. https://doi.org/10.1016/j.jacc.2020.10.027

8. Kamperidis N, Kamperidis V, Zegkos T, et al. Atherosclerosis and Inflammatory Bowel Disease-Shared Pathogenesis and Implications for Treatment. Angiology. 2021;72(4):303-314. https://doi.org/10.1177/0003319720974552

9. Миронова О.Ю., Исайкина М.А., Хасиева С.А. Атеросклероз и сердечно-сосудистый риск у пациентов с воспалительными заболеваниями кишечника. Терапевтический Архив. 2021;93(12):1533-8. https://doi.org/10.26442/00403660.2021.12.201225 [Mironova OIu, Isaikina MA, Khasieva SA. Аtherosclerosis and cardiovascular risk in patients with inflammatory bowel disease. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(12):1533-8 (in Russ.)]. https://doi.org/10.26442/00403660.2021.12.201225

10. Wu GC, Leng RX, Lu Q, Fan YG, Wang DG, Ye DQ. Subclinical Atherosclerosis in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Angiology. 2017;68(5):447-461. https://doi.org/10.1177/0003319716652031

11. Kristensen SL, Ahlehoff O, Lindhardsen J, et al. Prognosis after first-time myocardial infarction in patients with inflammatory bowel disease according to disease activity: nationwide cohort study. Circ Cardiovasc Qual Outcomes. 2014;7(6):857-862. https://doi.org/10.1161/CIRCOUTCOMES.114.000918

12. Kirchgesner J, Nyboe Andersen N, Carrat F, Jess T, Beaugerie L, BERENICE study group. Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study. Gut. 2020;69(5):852-858. https://doi.org/10.1136/gutjnl-2019-318932

13. Singh S, Kullo IJ, Pardi DS, Loftus EV. Epidemiology, risk factors and management of cardiovascular diseases in IBD. Nat Rev Gastroenterol Hepatol. 2015;12(1):26-35. https://doi.org/10.1038/nrgastro.2014.202

14. Peters MJL, Symmons DPM, McCarey D, et al. EULAR evidence based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69(2):325-331. https://doi.org/10.1136/ard.2009.113696

15. Damen JA, Pajouheshnia R, Heus P, et al. Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis. BMC Med. 2019;17(1):109. https://doi.org/10.1186/s12916-019-1340-7

16. Шелыгин ЮА, Ивашкин ВТ, Белоусова ЕА, et al. Язвенный колит (К51), взрослые. Колопроктология. 2023;22(1):10-44. https://doi.org/10.33878/2073-7556-2023-22-1-10-44 [Shelygin YuA, Ivashkin VT, Belousova EA, et al. Ulcerative colitis (K51), adults. Koloproktologia. 2023;22(1):10-44 (in Russ.)]. https://doi.org/10.33878/2073-7556-2023-22-1-10-44

17. Шелыгин Ю, Ивашкин В. Болезнь Крона. Министерство Здравоохранения Российской Федерации. 2024 [Shelygin Yu., Ivashkin V. Crohn's Disease. Ministry of Health of the Russian Federation. 2024.].

18. Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of Coronary Heart Disease Using Risk Factor Categories. Circulation. 1998;97(18):1837-1847. https://doi.org/10.1161/01.CIR.97.18.1837

19. Chen B, Collen LV, Mowat C, et al. Inflammatory Bowel Disease and Cardiovascular Diseases. Am J Med. 2022;135(12):1453-1460. https://doi.org/10.1016/j.amjmed.2022.08.012

20. Theocharidou E, Gossios TD, Griva T, et al. Is There an Association Between Inflammatory Bowel Diseases and Carotid Intima-media Thickness? Preliminary Data. Angiology. 2014;65(6):543-550. https://doi.org/10.1177/0003319713489876

21. Kothari HG, Gupta SJ, Gaikwad NR. Utility of Carotid Intima Media Thickness as an Auxiliary Vascular Parameter of Structural Alteration in Ulcerative Colitis. Inflamm Intest Dis. 2019;4(1):27-34. https://doi.org/10.1159/000499199

22. D’Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-753. https://doi.org/10.1161/CIRCULATIONAHA.107.699579

23. Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987-1003. https://doi.org/10.1016/s0195-668x(03)00114-3

24. Drosos GC, Vedder D, Houben E, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022;81(6):768-779. https://doi.org/10.1136/annrheumdis-2021-221733

25. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76(1):17-28. https://doi.org/10.1136/annrheumdis-2016-209775